NCT07018063 (YOUNG-NEOS) is a Phase 2 clinical trial of nab-paclitaxel in Gastric (Cardia, Body) Cancer, sponsored by zhoujing.

Who is sponsoring NCT07018063?

NCT07018063 is sponsored by zhoujing.

What drugs are being tested in NCT07018063?

Interventions in NCT07018063: nab-paclitaxel, oxaliplatin, S-1, sintilimab, D2 Gastrectomy.

What condition does NCT07018063 study?

NCT07018063 studies Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced.

Is NCT07018063 still recruiting?

NCT07018063 is currently not yet recruiting. Last updated 12 June 2025.

Last reviewed 2025-06-12 · How we verify

NCT07018063: YOUNG-NEOS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer

Not yet recruiting Phase 2 Last updated 12 June 2025

What this trial tests

Phase 2 trial testing nab-paclitaxel in Gastric (Cardia, Body) Cancer in 35 participants. Not yet recruiting.

Timeline

1 October 2025

Primary endpoint
30 December 2027

1 June 2030

Quick facts

Lead sponsor	zhoujing
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	1 October 2025
Primary completion	30 December 2027
Estimated completion	1 June 2030
Sites	1 location across China

Drugs / interventions tested

nab-paclitaxel (nab-paclitaxel) — full drug profile →
oxaliplatin (Oxaliplatin) — full drug profile →
S-1 — full drug profile →
sintilimab — full drug profile →
D2 Gastrectomy

Conditions studied

Gastric (Cardia, Body) Cancer — all drugs for Gastric (Cardia, Body) Cancer →
Stomach Adenocarcinoma — all drugs for Stomach Adenocarcinoma →
Locally Advanced — all drugs for Locally Advanced →

Sponsor

zhoujing

Who can join

Adults 16 to 45, any sex, with Gastric (Cardia, Body) Cancer or Stomach Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the effectiveness and safety of a preoperative treatment (called neoadjuvant therapy) combining four drugs-nab-paclitaxel, oxaliplatin, S-1, and sintilimab-for patients with locally advanced, resectable early-onset gastric cancer (diagnosed at age 45 or younger). All participants will receive this drug combination before undergoing surgery to remove the tumor. The goal is to shrink the tumor, increase the chance of complete surgical removal, and improve long-term outcomes. This is a single-arm, open-label, phase II clinical trial, meaning all participants will receive the same treatment, and both doctors and patients will know what drugs are being used. The study is being conducted at Peking University People's Hospital.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of nab-paclitaxel

Trials testing the same drug.

NCT05562297 — Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer · Phase 2 · not yet recruiting
NCT06528093 — A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Ta · Phase 1 · terminated
NCT06445062 — Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06390059 — EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Li · Phase 2 · active not recruiting
NCT05633914 — Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer · Phase 2 · unknown

Other recruiting trials for Gastric (Cardia, Body) Cancer

Currently open trials in the same condition.

NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07018063 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by zhoujing
Last refreshed: 12 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07018063.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing